市場調查報告書
商品編碼
1380449
2023-2030 年全球戒菸與尼古丁戒菸市場Global Smoking Cessation and Nicotine De-addiction Market 2023-2030 |
全球戒菸和尼古丁戒菸市場根據類型和配銷通路進行細分。根據類型,市場分為 NTR、藥物治療、電子煙。根據配銷通路,市場分為醫院藥房、藥局、零售店和網路商店。在配銷通路中,醫院藥房細分市場由於產品標準和消費者信任的良好保證,預計將佔據相當大的市場佔有率。在大多數國家,尼古丁口香糖和其他尼古丁替代產品的銷售僅限於藥局。
在這些類型中,NTR 細分市場由於其易用性、可及性增加以及減少吸菸者對尼古丁渴望的有效性,預計將佔據顯著的市場佔有率。 NTR 以口香糖、貼片、噴霧、吸入器或含片的形式提供單獨的尼古丁,但不提供菸草中的其他有害化學物質。 NRT 可以幫助緩解一些身體戒斷症狀,以便您可以專注於戒菸的心理(情緒)方面。據世界衛生組織稱,菸草流行對全球公共衛生危害最大,每年造成超過 800 萬人死亡。其中約 130 萬人是由非吸菸者接觸二手菸造成的,而超過 700 萬人是由直接吸菸造成的。 NRT 產品能夠有效幫助人們戒菸,並被廣泛用於戒菸困難的吸菸者。 2017 年至 2020 年間,場外 NTR 銷售額每年總計約 10 億美元。 2020年,含片佔非處方尼古丁替代療法銷售額的33.3%(3.22億美元),口香糖佔52.7%(5.11億美元),貼片佔非處方尼古丁替代療法銷售額的14.1%(1.37億美元) 。藥局在非處方尼古丁替代療法總銷售額中所佔比例最大(42.9%)。
全球戒菸和尼古丁戒菸市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(義大利、西班牙、德國、法國等)、亞太地區(印度、中國、日本) 、韓國等)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,歐洲區域市場預計在預測期內將大幅成長。含尼古丁的OTC戒菸產品是英國等國最受歡迎的尼古丁替代療法(NRT)產品。公眾對戒菸好處的認知不斷提高以及戒菸計畫數量的增加推動了歐洲市場的發展。
由於發達的醫療基礎設施以及可自由支配支出的收入不斷成長,北美在戒菸和尼古丁戒菸市場中佔據主導地位。根據美國醫學會(AMA)的數據,2020年美國醫療保健支出成長9.7%,達到4.1兆美元,即人均12,530美元。該地區對電子煙產品的強勁需求也對北美戒菸和尼古丁脫癮市場的成長起到了重要作用。電子煙是第二常用的菸草產品,2019 年有 4.5%(1,090 萬)的美國成年人使用過該產品。預計由於偏好的轉變,北美地區將以顯著的速度擴張各國消費者傾向於使用植物性尼古丁戒癮相關產品的情況。
服務全球戒菸和尼古丁戒菸市場的主要公司包括:英美菸草公司、雷迪博士實驗室有限公司、葛蘭素史克公司、帝國品牌公司、日本菸草公司、JUUL Labs, Inc.、菲利普莫里斯國際公司Inc.、Niconovum AB、Perrigo Company plc、OncoGenex Pharmaceuticals Inc、NJOY, LLC、InnokinTechnology 等。市場參與者透過各種策略(包括併購、合作、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2020年5月,Cipla Health的戒菸品牌Nicotex與卡納塔克邦和果阿邦政府合作,為在COVID-19爆發期間從事高度脆弱性的第一線工作人員提供尼古丁替代療法(NRT)。
Title: Global Smoking Cessation and Nicotine De-Addiction Market Size, Share & Trends Analysis Report by Types (Nicotine Replacement Therapy (NRT), Drug Therapy, and E-Cigarettes), and by Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Stores, and Online Stores)Forecast Period (2023-2030).
Global smoking cessation and nicotine de-addiction market is anticipated to grow at a CAGR of 15.2 % during the forecast period. The smoking cessation and nicotine de-addiction market has witnessed significant growth due to health disadvantages of smoking such as lung cancer, cardiac diseases, and other respiratory problems, initiatives supported by governments to raise awareness about the harmful effects of smoking through the use of informational brochures, warning labels, dissuasive imagery on cigarette packages, television advertisements, and newspapers.
The global smoking cessation and nicotine de-addiction market is segmented based on the type, and distribution channel. Based on the type, the market is sub-segmented into NTR, drug therapy, e-cigarettes. Based on distribution channel, the market is sub-segmented into hospitals pharmacies, drug stores, retail stores and online stores. Among the distribution channel, the hospitals pharmacies sub-segment is anticipated to hold a considerable share of the market due to good assurance of product standards and consumer trust. In most countries, sales of nicotine gum and other nicotine replacement products are restricted to pharmacy shops.
Among the types, NTR sub-segment is anticipated to hold a prominent share of the market due to its ease of use, its increased accessibility, and its effectiveness in reducing the nicotine craving in smokers. NTR gives individual nicotine in the form of gum, patches, sprays, inhalers, or lozenges but not the other harmful chemicals in tobacco. NRT can help relieve some of the physical withdrawal symptoms so that you can focus on the psychological (emotional) aspects of quitting. According to WHO tobacco epidemic the greatest hazards to global public health, killing more than 8 million people annually. Around 1.3 million of those fatalities are caused by non-smokers being exposed to secondhand smoke, whereas more than 7 million are caused by direct tobacco use. NRT products have been effective in helping people quit smoking and are widely used among smokers struggling to quit. Between 2017 and 2020 over-the-counter NTR sales totaled about $1 billion annually. In 2020, lozenges accounted for 33.3 per cent ($322 million), gum accounted for 52.7% ($511 million) and patches accounted for 14.1% ($137 million) of over-the-counter nicotine replacement therapy sales. Drug stores were accounting for the largest percentage of total over-the-counter nicotine replacement therapy sales (42.9%).
The global smoking cessation and nicotine de-addiction market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Europe regional market is expected to grow considerably over the forecast period. Nicotine-containing OTC smoking cessation products are the most preferred nicotine replacement therapy (NRT) products in the countries such as UK. The market in Europe is being driven by increased public awareness of the advantages of quitting smoking and a rise in the number of smoking cessations programmes.
North America is dominating the smoking cessation and nicotine de-addiction market, due to the developed healthcare infrastructure as well as the growing incomes available for discretionary spending. According to the American Medical Association (AMA), health spending in the US increased by 9.7% in 2020 and reached to $4.1 trillion or $12,530 per capita. Region's strong demand for e-cigarette products also played a major role in increasing smoking cessation and nicotine de-addiction market in North America. E-cigarettes were the second most commonly used tobacco product, with 4.5% (10.9 million) of the US adults reporting use of the product in 2019. It is anticipated that the North American region will expand at a significant rate due to the shifting preferences of consumers towards the utilization of plant-based, nicotine de-addiction-related products in countries.
The major companies serving the global smoking cessation and nicotine de-addiction market include: British American Tobacco Plc, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline Plc, Imperial Brands Plc, Japan Tobacco, Inc., JUUL Labs, Inc., Philip Morris International Inc., Niconovum AB, Perrigo Company plc, OncoGenex Pharmaceuticals Inc, NJOY, LLC, InnokinTechnology and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2020, Nicotex, Cipla Health's smoking cessation brand, collaborated with Karnataka and Goa governments to provide Nicotine Replacement Therapy (NRT) to frontline workers, who are engaged in field work under high vulnerability amidst the COVID-19 outbreak.